Interested in Participating?

We are looking for contributors to author, edit, and peer review our vast library of review articles and multiple choice questions. In as little as 2-3 hours you can make a significant contribution to your specialty. In return for a small amount of your time, you will receive free access to all content and you will be published as an author or editor in eBooks, apps, online CME/CE activities, and an online Learning Management System for students, teachers, and program directors that allows access to review materials in over 500 specialties.

Improve Content - Become an Author or Editor

This is an academic project designed to provide inexpensive peer-reviewed Apps, eBooks, and very soon an online CME/CE system to help students identify weaknesses and improve knowledge. We would like you to consider being an author or editor. Please click here to learn more. Thank you for you for your interest, the StatPearls Publishing Editorial Team.

Cancer, Acute Myeloid Leukemia (AML, Erythroid Leukemia, Myelodysplasia-Related Leukemia, BCR-ABL Chronic Leukemia) - References


Bain BJ,Béné MC, Morphological and Immunophenotypic Clues to the WHO Categories of Acute Myeloid Leukaemia. Acta haematologica. 2019 Apr 9;     [PubMed]
Naymagon L,Marcellino B,Mascarenhas J, Eosinophilia in acute myeloid leukemia: Overlooked and underexamined. Blood reviews. 2019 Mar 30;     [PubMed]
Medeiros BC,Chan SM,Daver NG,Jonas BA,Pollyea DA, Optimizing survival outcomes with post-remission therapy in acute myeloid leukemia. American journal of hematology. 2019 Apr 3;     [PubMed]
Hartmann L,Metzeler KH, Clonal hematopoiesis and pre-leukemia -genetics, biology and clinical implications. Genes, chromosomes     [PubMed]
Boddu PC,Zeidan AM, Myeloid disorders after autoimmune disease. Best practice     [PubMed]
Liu XJ,Huang XJ,Xu LP,Liu KY,Zhang XH,Yan CH,Wang Y, [Effects of pre-transplant course on prognosis of allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019 Mar 14;     [PubMed]
Leisch M,Jansko B,Zaborsky N,Greil R,Pleyer L, Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and/or Modulation? Cancers. 2019 Feb 21;     [PubMed]
Dong XY,Li YL,Jiang L,Wu CY,Shang BJ,Zhang L,Cheng W,Zhu ZM, [Correlation between myeloperoxidase expression and gene alterations and prognosis in acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2019 Jan 14;     [PubMed]
Schmid C,Labopin M,Schaap N,Veelken H,Schleuning M,Stadler M,Finke J,Hurst E,Baron F,Ringden O,Bug G,Blaise D,Tischer J,Bloor A,Esteve J,Giebel S,Savani B,Gorin NC,Ciceri F,Mohty M,Nagler A, Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukaemia - a matched pair analysis by the Acute Leukaemia Working Party of EBMT. British journal of haematology. 2019 Mar;     [PubMed]
Nabhan C,Kamat S,Karl Kish J, Acute myeloid leukemia in the elderly: what constitutes treatment value? Leukemia     [PubMed]
Duan WB,Gong LZ,Jia JS,Zhu HH,Zhao XS,Jiang Q,Zhao T,Wang J,Qin YZ,Huang XJ,Jiang H, [Clinical features and early treatment effects in intermediate risk and poor risk acute myeloid leukemia with EVI1 positive]. Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences. 2017 Dec 18;     [PubMed]
Lin M,Chen B, Advances in the drug therapies of acute myeloid leukemia (except acute wpromyelocytic leukemia). Drug design, development and therapy. 2018;     [PubMed]
Schoen MW,Woelich SK,Braun JT,Reddy DV,Fesler MJ,Petruska PJ,Freter CE,Lionberger JM, Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk. Leukemia research. 2018 May;     [PubMed]
Strickland SA,Shaver AC,Byrne M,Daber RD,Ferrell PB,Head DR,Mohan SR,Mosse CA,Moyo TK,Stricker TP,Vnencak-Jones C,Savona MR,Seegmiller AC, Genotypic and clinical heterogeneity within NCCN favorable-risk acute myeloid leukemia. Leukemia research. 2018 Feb;     [PubMed]
Fujiwara Y,Yamaguchi H,Yui S,Tokura T,Inai K,Onai D,Omori I,Marumo A,Yamanaka S,Sakaguchi M,Terada K,Nakagome S,Arai K,Kitano T,Okabe M,Okamoto M,Tamai H,Nakayama K,Tajika K,Wakita S,Inokuchi K, Importance of prognostic stratification via gene mutation analysis in elderly patients with acute myelogenous leukemia. International journal of laboratory hematology. 2019 Apr 10;     [PubMed]
Niu P,Yao B,Wei L,Zhu H,Fang C,Zhao Y, Construction of prognostic risk prediction model based on high-throughput sequencing expression profile data in childhood acute myeloid leukemia. Blood cells, molecules     [PubMed]


The intent of StatPearls is to provide practice questions and explanations to assist you in identifying and resolving knowledge deficits. These questions and explanations are not intended to be a source of the knowledge base of all of medicine, nor is it intended to be a board or certification review of Lab-Clinical Laboratory Scientist (MT). The authors or editors do not warrant the information is complete or accurate. The reader is encouraged to verify each answer and explanation in several references. All drug indications and dosages should be verified before administration.

StatPearls offers the most comprehensive database of free multiple-choice questions with explanations and short review chapters ever developed. This system helps physicians, medical students, dentists, nurses, pharmacists, and allied health professionals identify education deficits and learn new concepts. StatPearls is not a board or certification review system for Lab-Clinical Laboratory Scientist (MT), it is a learning system that you can use to help improve your knowledge base of medicine for life-long learning. StatPearls will help you identify your weaknesses so that when you are ready to study for a board or certification exam in Lab-Clinical Laboratory Scientist (MT), you will already be prepared.

Our content is updated continuously through a multi-step peer review process that will help you be prepared and review for a thorough knowledge of Lab-Clinical Laboratory Scientist (MT). When it is time for the Lab-Clinical Laboratory Scientist (MT) board and certification exam, you will already be ready. Besides online study quizzes, we also publish our peer-reviewed content in eBooks and mobile Apps. We also offer inexpensive CME/CE, so our content can be used to attain education credits while you study Lab-Clinical Laboratory Scientist (MT).